TY - JOUR
T1 - Histiocytic disorders
AU - McClain, Kenneth L.
AU - Bigenwald, Camille
AU - Collin, Matthew
AU - Haroche, Julien
AU - Marsh, Rebecca A.
AU - Merad, Miriam
AU - Picarsic, Jennifer
AU - Ribeiro, Karina B.
AU - Allen, Carl E.
N1 - Publisher Copyright:
© 2021, Springer Nature Limited.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - The historic term ‘histiocytosis’ meaning ‘tissue cell’ is used as a unifying concept for diseases characterized by pathogenic myeloid cells that share histological features with macrophages or dendritic cells. These cells may arise from the embryonic yolk sac, fetal liver or postnatal bone marrow. Prior classification schemes align disease designation with terminal phenotype: for example, Langerhans cell histiocytosis (LCH) shares CD207+ antigen with physiological epidermal Langerhans cells. LCH, Erdheim–Chester disease (ECD), juvenile xanthogranuloma (JXG) and Rosai–Dorfman disease (RDD) are all characterized by pathological ERK activation driven by activating somatic mutations in MAPK pathway genes. The title of this Primer (Histiocytic disorders) was chosen to differentiate the above diseases from Langerhans cell sarcoma and malignant histiocytosis, which are hyperproliferative lesions typical of cancer. By comparison LCH, ECD, RDD and JXG share some features of malignant cells including activating MAPK pathway mutations, but are not hyperproliferative. ‘Inflammatory myeloproliferative neoplasm’ may be a more precise nomenclature. By contrast, haemophagocytic lymphohistiocytosis is associated with macrophage activation and extreme inflammation, and represents a syndrome of immune dysregulation. These diseases affect children and adults in varying proportions depending on which of the entities is involved.
AB - The historic term ‘histiocytosis’ meaning ‘tissue cell’ is used as a unifying concept for diseases characterized by pathogenic myeloid cells that share histological features with macrophages or dendritic cells. These cells may arise from the embryonic yolk sac, fetal liver or postnatal bone marrow. Prior classification schemes align disease designation with terminal phenotype: for example, Langerhans cell histiocytosis (LCH) shares CD207+ antigen with physiological epidermal Langerhans cells. LCH, Erdheim–Chester disease (ECD), juvenile xanthogranuloma (JXG) and Rosai–Dorfman disease (RDD) are all characterized by pathological ERK activation driven by activating somatic mutations in MAPK pathway genes. The title of this Primer (Histiocytic disorders) was chosen to differentiate the above diseases from Langerhans cell sarcoma and malignant histiocytosis, which are hyperproliferative lesions typical of cancer. By comparison LCH, ECD, RDD and JXG share some features of malignant cells including activating MAPK pathway mutations, but are not hyperproliferative. ‘Inflammatory myeloproliferative neoplasm’ may be a more precise nomenclature. By contrast, haemophagocytic lymphohistiocytosis is associated with macrophage activation and extreme inflammation, and represents a syndrome of immune dysregulation. These diseases affect children and adults in varying proportions depending on which of the entities is involved.
UR - http://www.scopus.com/inward/record.url?scp=85116812217&partnerID=8YFLogxK
U2 - 10.1038/s41572-021-00307-9
DO - 10.1038/s41572-021-00307-9
M3 - Review article
C2 - 34620874
AN - SCOPUS:85116812217
SN - 2056-676X
VL - 7
JO - Nature Reviews Disease Primers
JF - Nature Reviews Disease Primers
IS - 1
M1 - 73
ER -